Renal dysfunction during and after high-dose methotrexate View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2009-03

AUTHORS

Myke R. Green, Marc C. Chamberlain

ABSTRACT

PURPOSE: To evaluate renal dysfunction in adult patients encountered during and immediately after repeated administrations of high-dose methotrexate (HDMTX) for treatment of primary central nervous system lymphoma (PCNSL). METHODS: In this single-center, retrospective, open label trial, 23 consecutive adult patients aged between 19 and 94 years diagnosed with PCNSL were given >or=4 consecutive cycles of HDMTX (8 gm/m(2)/dose) every 14 days as per institution protocol. Serum creatinine and serum methotrexate levels were measured at 24, 48 and 72 h after beginning of HDMTX infusion. RESULTS: Forty-eight percent of all patients (30% of all HDMTX cycles) experienced a >or=200% increase in baseline creatinine during treatment. Nine percent of patients met requirements for administration of carboxypeptidase-G(2) (glucarpidase) under compassionate use from National Cancer Institute. Thirty percent of patients at the conclusion of HDMTX therapy demonstrated a NCI Common Toxicity Criteria (CTC) grade 2 or higher increase in post-treatment serum creatinine compared to pre-treatment serum creatinine amongst whom ten patients (43%) had levels outside of the normal range. CONCLUSION: Renal dysfunction of CTC grade 2, 3 or 4 is common during treatment with HDMTX in the treatment of PCNSL, occurring in 40% of all cycles. Renal dysfunction persists at least 4 months following the conclusion of therapy in nearly 30% of patients. Male patients age greater than 50 years are at greatest risk of renal dysfunction. More... »

PAGES

599

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00280-008-0772-0

DOI

http://dx.doi.org/10.1007/s00280-008-0772-0

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1051816335

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/18504579


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antimetabolites, Antineoplastic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Case-Control Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Central Nervous System Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Creatinine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dose-Response Relationship, Drug", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kidney", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kidney Diseases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lymphoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Methotrexate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Young Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "gamma-Glutamyl Hydrolase", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "Department of Pharmacy, Intermountain Healthcare Corporation, Salt Lake City, UT, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Green", 
        "givenName": "Myke R.", 
        "id": "sg:person.01130147607.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01130147607.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Seattle Cancer Care Alliance", 
          "id": "https://www.grid.ac/institutes/grid.430269.a", 
          "name": [
            "Department of Neurology and Neurological Surgery, Seattle Cancer Care Alliance, University of Washington/Fred Hutchinson Cancer, Research Center, 895 Eastlake Avenue E, Mail-stop: G-6800, PO Box\u00a010923, 98109-1023, Seattle, WA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chamberlain", 
        "givenName": "Marc C.", 
        "id": "sg:person.01326261166.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01326261166.36"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1002/1097-0142(19890315)63:6+<995::aid-cncr2820631302>3.0.co;2-r", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006543131"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1081/cnv-100102557", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007913345"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1634/theoncologist.11-6-694", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035791649"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00002512-200320110-00003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040130490", 
          "https://doi.org/10.2165/00002512-200320110-00003"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00002512-200320110-00003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040130490", 
          "https://doi.org/10.2165/00002512-200320110-00003"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0002-9343(80)90105-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040671266"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1586/14737175.6.5.635", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046487221"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1081/clt-120028740", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049124713"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2217/14750708.3.4.495", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049594325"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1159/000180580", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051087304"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.6004/jnccn.2005.0038", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1077120284"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.6004/jnccn.2005.0038", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1077120284"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077836518", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1997.15.5.2125", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083094801"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2009-03", 
    "datePublishedReg": "2009-03-01", 
    "description": "PURPOSE: To evaluate renal dysfunction in adult patients encountered during and immediately after repeated administrations of high-dose methotrexate (HDMTX) for treatment of primary central nervous system lymphoma (PCNSL).\nMETHODS: In this single-center, retrospective, open label trial, 23 consecutive adult patients aged between 19 and 94 years diagnosed with PCNSL were given >or=4 consecutive cycles of HDMTX (8 gm/m(2)/dose) every 14 days as per institution protocol. Serum creatinine and serum methotrexate levels were measured at 24, 48 and 72 h after beginning of HDMTX infusion.\nRESULTS: Forty-eight percent of all patients (30% of all HDMTX cycles) experienced a >or=200% increase in baseline creatinine during treatment. Nine percent of patients met requirements for administration of carboxypeptidase-G(2) (glucarpidase) under compassionate use from National Cancer Institute. Thirty percent of patients at the conclusion of HDMTX therapy demonstrated a NCI Common Toxicity Criteria (CTC) grade 2 or higher increase in post-treatment serum creatinine compared to pre-treatment serum creatinine amongst whom ten patients (43%) had levels outside of the normal range.\nCONCLUSION: Renal dysfunction of CTC grade 2, 3 or 4 is common during treatment with HDMTX in the treatment of PCNSL, occurring in 40% of all cycles. Renal dysfunction persists at least 4 months following the conclusion of therapy in nearly 30% of patients. Male patients age greater than 50 years are at greatest risk of renal dysfunction.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00280-008-0772-0", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1088364", 
        "issn": [
          "0344-5704", 
          "1432-0843"
        ], 
        "name": "Cancer Chemotherapy and Pharmacology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "63"
      }
    ], 
    "name": "Renal dysfunction during and after high-dose methotrexate", 
    "pagination": "599", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "f6d2f63c5d1cf1a3d077ee460e6bdb34297009e76b74a201947fc760b3f6b24d"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "18504579"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "7806519"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00280-008-0772-0"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1051816335"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00280-008-0772-0", 
      "https://app.dimensions.ai/details/publication/pub.1051816335"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T14:34", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000373_0000000373/records_13106_00000001.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs00280-008-0772-0"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00280-008-0772-0'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00280-008-0772-0'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00280-008-0772-0'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00280-008-0772-0'


 

This table displays all metadata directly associated to this object as RDF triples.

202 TRIPLES      21 PREDICATES      63 URIs      43 LITERALS      31 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00280-008-0772-0 schema:about N3107e445489d4da8bc266e688ccc0a1e
2 N3657bdd6885a4a339541a80b83f90061
3 N3ab941e3306d41b980074e0f7e14004a
4 N5e145c59933b41fca4deb9d570c5361e
5 N5e741130f376456a93324888682fb356
6 N6431a7fd87b448eba83713a58b644e55
7 N698c1961f02d4138a1a59fbe3a28cfb4
8 N77481590992b4f53a78d9554ba7f1097
9 N7d5c6938b98e4d1bb9d525f5764e3bcc
10 N7f5aeac0b16d4680876bff7976bb81d7
11 Na3cd6d0aa4534cf0828000695640fe63
12 Na9c5417c6cb3435891f9ab86c036a236
13 Nac79ed604be8484cb622f436011b833a
14 Nbe2897b8494d404abb3c43c78793ade5
15 Nc480ef12adff47e0a639cfb0927f5b34
16 Nc67b6e8e1a2149b39fd7027756ea69e3
17 Nc72c17b67434406db56a51c09f6cc880
18 Nd7830956c84c46c985c716b583c5bc0f
19 Ne4a019e272524507a20916ed552e23a0
20 Nf5fa1084adb24abb9232319479d1527e
21 Nf90debfb83724ca69142321788be7188
22 Nfd1d175994874f218b85ca87b63cbcc6
23 anzsrc-for:11
24 anzsrc-for:1103
25 schema:author N72f117b20c494f439e3cf84fb6230931
26 schema:citation sg:pub.10.2165/00002512-200320110-00003
27 https://app.dimensions.ai/details/publication/pub.1077836518
28 https://doi.org/10.1002/1097-0142(19890315)63:6+<995::aid-cncr2820631302>3.0.co;2-r
29 https://doi.org/10.1016/0002-9343(80)90105-9
30 https://doi.org/10.1081/clt-120028740
31 https://doi.org/10.1081/cnv-100102557
32 https://doi.org/10.1159/000180580
33 https://doi.org/10.1200/jco.1997.15.5.2125
34 https://doi.org/10.1586/14737175.6.5.635
35 https://doi.org/10.1634/theoncologist.11-6-694
36 https://doi.org/10.2217/14750708.3.4.495
37 https://doi.org/10.6004/jnccn.2005.0038
38 schema:datePublished 2009-03
39 schema:datePublishedReg 2009-03-01
40 schema:description PURPOSE: To evaluate renal dysfunction in adult patients encountered during and immediately after repeated administrations of high-dose methotrexate (HDMTX) for treatment of primary central nervous system lymphoma (PCNSL). METHODS: In this single-center, retrospective, open label trial, 23 consecutive adult patients aged between 19 and 94 years diagnosed with PCNSL were given >or=4 consecutive cycles of HDMTX (8 gm/m(2)/dose) every 14 days as per institution protocol. Serum creatinine and serum methotrexate levels were measured at 24, 48 and 72 h after beginning of HDMTX infusion. RESULTS: Forty-eight percent of all patients (30% of all HDMTX cycles) experienced a >or=200% increase in baseline creatinine during treatment. Nine percent of patients met requirements for administration of carboxypeptidase-G(2) (glucarpidase) under compassionate use from National Cancer Institute. Thirty percent of patients at the conclusion of HDMTX therapy demonstrated a NCI Common Toxicity Criteria (CTC) grade 2 or higher increase in post-treatment serum creatinine compared to pre-treatment serum creatinine amongst whom ten patients (43%) had levels outside of the normal range. CONCLUSION: Renal dysfunction of CTC grade 2, 3 or 4 is common during treatment with HDMTX in the treatment of PCNSL, occurring in 40% of all cycles. Renal dysfunction persists at least 4 months following the conclusion of therapy in nearly 30% of patients. Male patients age greater than 50 years are at greatest risk of renal dysfunction.
41 schema:genre research_article
42 schema:inLanguage en
43 schema:isAccessibleForFree false
44 schema:isPartOf N754d8a19ea634550b96b48eb323b4f80
45 Nd62c7ce8620a4a429333939e68a83fe4
46 sg:journal.1088364
47 schema:name Renal dysfunction during and after high-dose methotrexate
48 schema:pagination 599
49 schema:productId N208ab54ffe4543faa00e00bf83c20d8f
50 N3a91a2e132104aba9063b93b6c5957b6
51 N3b0b640ab00047b7b245aaad57ffa4b9
52 N6decd12fb4134afeacc54e7b0e35b5dd
53 Na421b3dc9c88459f9cadc569e7d4e584
54 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051816335
55 https://doi.org/10.1007/s00280-008-0772-0
56 schema:sdDatePublished 2019-04-11T14:34
57 schema:sdLicense https://scigraph.springernature.com/explorer/license/
58 schema:sdPublisher Neaae930194cc44dfb364d0ece21d1fd7
59 schema:url http://link.springer.com/10.1007%2Fs00280-008-0772-0
60 sgo:license sg:explorer/license/
61 sgo:sdDataset articles
62 rdf:type schema:ScholarlyArticle
63 N208ab54ffe4543faa00e00bf83c20d8f schema:name doi
64 schema:value 10.1007/s00280-008-0772-0
65 rdf:type schema:PropertyValue
66 N3107e445489d4da8bc266e688ccc0a1e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
67 schema:name Prognosis
68 rdf:type schema:DefinedTerm
69 N3657bdd6885a4a339541a80b83f90061 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
70 schema:name Creatinine
71 rdf:type schema:DefinedTerm
72 N3a91a2e132104aba9063b93b6c5957b6 schema:name nlm_unique_id
73 schema:value 7806519
74 rdf:type schema:PropertyValue
75 N3ab941e3306d41b980074e0f7e14004a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
76 schema:name Case-Control Studies
77 rdf:type schema:DefinedTerm
78 N3b0b640ab00047b7b245aaad57ffa4b9 schema:name dimensions_id
79 schema:value pub.1051816335
80 rdf:type schema:PropertyValue
81 N441a581110ae44a2a53a4f13a08e720b rdf:first sg:person.01326261166.36
82 rdf:rest rdf:nil
83 N47695dc559c74feebe660a8cff6b1670 schema:name Department of Pharmacy, Intermountain Healthcare Corporation, Salt Lake City, UT, USA
84 rdf:type schema:Organization
85 N5e145c59933b41fca4deb9d570c5361e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
86 schema:name Female
87 rdf:type schema:DefinedTerm
88 N5e741130f376456a93324888682fb356 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
89 schema:name Young Adult
90 rdf:type schema:DefinedTerm
91 N6431a7fd87b448eba83713a58b644e55 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
92 schema:name Survival Rate
93 rdf:type schema:DefinedTerm
94 N698c1961f02d4138a1a59fbe3a28cfb4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
95 schema:name Dose-Response Relationship, Drug
96 rdf:type schema:DefinedTerm
97 N6decd12fb4134afeacc54e7b0e35b5dd schema:name readcube_id
98 schema:value f6d2f63c5d1cf1a3d077ee460e6bdb34297009e76b74a201947fc760b3f6b24d
99 rdf:type schema:PropertyValue
100 N72f117b20c494f439e3cf84fb6230931 rdf:first sg:person.01130147607.51
101 rdf:rest N441a581110ae44a2a53a4f13a08e720b
102 N754d8a19ea634550b96b48eb323b4f80 schema:volumeNumber 63
103 rdf:type schema:PublicationVolume
104 N77481590992b4f53a78d9554ba7f1097 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Male
106 rdf:type schema:DefinedTerm
107 N7d5c6938b98e4d1bb9d525f5764e3bcc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Middle Aged
109 rdf:type schema:DefinedTerm
110 N7f5aeac0b16d4680876bff7976bb81d7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Lymphoma
112 rdf:type schema:DefinedTerm
113 Na3cd6d0aa4534cf0828000695640fe63 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name gamma-Glutamyl Hydrolase
115 rdf:type schema:DefinedTerm
116 Na421b3dc9c88459f9cadc569e7d4e584 schema:name pubmed_id
117 schema:value 18504579
118 rdf:type schema:PropertyValue
119 Na9c5417c6cb3435891f9ab86c036a236 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Kidney Diseases
121 rdf:type schema:DefinedTerm
122 Nac79ed604be8484cb622f436011b833a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Kidney
124 rdf:type schema:DefinedTerm
125 Nbe2897b8494d404abb3c43c78793ade5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Humans
127 rdf:type schema:DefinedTerm
128 Nc480ef12adff47e0a639cfb0927f5b34 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Central Nervous System Neoplasms
130 rdf:type schema:DefinedTerm
131 Nc67b6e8e1a2149b39fd7027756ea69e3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Methotrexate
133 rdf:type schema:DefinedTerm
134 Nc72c17b67434406db56a51c09f6cc880 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Adult
136 rdf:type schema:DefinedTerm
137 Nd62c7ce8620a4a429333939e68a83fe4 schema:issueNumber 4
138 rdf:type schema:PublicationIssue
139 Nd7830956c84c46c985c716b583c5bc0f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Treatment Outcome
141 rdf:type schema:DefinedTerm
142 Ne4a019e272524507a20916ed552e23a0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Retrospective Studies
144 rdf:type schema:DefinedTerm
145 Neaae930194cc44dfb364d0ece21d1fd7 schema:name Springer Nature - SN SciGraph project
146 rdf:type schema:Organization
147 Nf5fa1084adb24abb9232319479d1527e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Aged
149 rdf:type schema:DefinedTerm
150 Nf90debfb83724ca69142321788be7188 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Aged, 80 and over
152 rdf:type schema:DefinedTerm
153 Nfd1d175994874f218b85ca87b63cbcc6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Antimetabolites, Antineoplastic
155 rdf:type schema:DefinedTerm
156 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
157 schema:name Medical and Health Sciences
158 rdf:type schema:DefinedTerm
159 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
160 schema:name Clinical Sciences
161 rdf:type schema:DefinedTerm
162 sg:journal.1088364 schema:issn 0344-5704
163 1432-0843
164 schema:name Cancer Chemotherapy and Pharmacology
165 rdf:type schema:Periodical
166 sg:person.01130147607.51 schema:affiliation N47695dc559c74feebe660a8cff6b1670
167 schema:familyName Green
168 schema:givenName Myke R.
169 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01130147607.51
170 rdf:type schema:Person
171 sg:person.01326261166.36 schema:affiliation https://www.grid.ac/institutes/grid.430269.a
172 schema:familyName Chamberlain
173 schema:givenName Marc C.
174 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01326261166.36
175 rdf:type schema:Person
176 sg:pub.10.2165/00002512-200320110-00003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040130490
177 https://doi.org/10.2165/00002512-200320110-00003
178 rdf:type schema:CreativeWork
179 https://app.dimensions.ai/details/publication/pub.1077836518 schema:CreativeWork
180 https://doi.org/10.1002/1097-0142(19890315)63:6+<995::aid-cncr2820631302>3.0.co;2-r schema:sameAs https://app.dimensions.ai/details/publication/pub.1006543131
181 rdf:type schema:CreativeWork
182 https://doi.org/10.1016/0002-9343(80)90105-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040671266
183 rdf:type schema:CreativeWork
184 https://doi.org/10.1081/clt-120028740 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049124713
185 rdf:type schema:CreativeWork
186 https://doi.org/10.1081/cnv-100102557 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007913345
187 rdf:type schema:CreativeWork
188 https://doi.org/10.1159/000180580 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051087304
189 rdf:type schema:CreativeWork
190 https://doi.org/10.1200/jco.1997.15.5.2125 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083094801
191 rdf:type schema:CreativeWork
192 https://doi.org/10.1586/14737175.6.5.635 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046487221
193 rdf:type schema:CreativeWork
194 https://doi.org/10.1634/theoncologist.11-6-694 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035791649
195 rdf:type schema:CreativeWork
196 https://doi.org/10.2217/14750708.3.4.495 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049594325
197 rdf:type schema:CreativeWork
198 https://doi.org/10.6004/jnccn.2005.0038 schema:sameAs https://app.dimensions.ai/details/publication/pub.1077120284
199 rdf:type schema:CreativeWork
200 https://www.grid.ac/institutes/grid.430269.a schema:alternateName Seattle Cancer Care Alliance
201 schema:name Department of Neurology and Neurological Surgery, Seattle Cancer Care Alliance, University of Washington/Fred Hutchinson Cancer, Research Center, 895 Eastlake Avenue E, Mail-stop: G-6800, PO Box 10923, 98109-1023, Seattle, WA, USA
202 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...